JX-594: Interim Phase II data

Interim data from 7 evaluable patients in a Phase II trial showed that IV and intratumoral doses of JX-594 followed by Nexavar sorafenib produced 1 partial response and 5 cases of stable disease as measured by RECIST criteria, with 6 patients achieving Choi necrotic responses. The treatment regimen was well tolerated. Data were presented at the International Liver Cancer Association meeting in Montreal. JX-594 has Orphan Drug designation in Europe to treat HCC...